IKNA

Ikena Oncology (IKNA)

About Ikena Oncology (IKNA)

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Details

Daily high

$1.38

Daily low

$1.33

Price at open

$1.36

52 Week High

$1.94

52 Week Low

$1.22

Market cap

53.9M

Dividend yield

0.00%

Volume

71,815

Avg. volume

74,051

P/E ratio

-1.31

Ikena Oncology News